Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Ovid Therapeutics stock

OVID
US6904691010
A2DQ8S

Price

1.05
Today +/-
+0.02
Today %
+2.09 %
P

Ovid Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ovid Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ovid Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ovid Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ovid Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ovid Therapeutics Stock Price History

DateOvid Therapeutics Price
11/19/20241.05 undefined
11/19/20241.03 undefined
11/18/20241.04 undefined
11/15/20241.06 undefined
11/14/20241.15 undefined
11/13/20241.17 undefined
11/12/20241.24 undefined
11/11/20241.36 undefined
11/8/20241.30 undefined
11/7/20241.30 undefined
11/6/20241.30 undefined
11/5/20241.25 undefined
11/4/20241.18 undefined
11/1/20241.14 undefined
10/31/20241.13 undefined
10/30/20241.15 undefined
10/29/20241.19 undefined
10/28/20241.17 undefined
10/25/20241.18 undefined
10/24/20241.21 undefined
10/23/20241.20 undefined
10/22/20241.19 undefined

Ovid Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ovid Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ovid Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ovid Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ovid Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ovid Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ovid Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ovid Therapeutics’s growth potential.

Ovid Therapeutics Revenue, EBIT and net profit per share

DateOvid Therapeutics RevenueOvid Therapeutics EBITOvid Therapeutics Net Income
2029e121.68 M undefined0 undefined-24.61 M undefined
2028e71.95 M undefined-44.05 M undefined-29.68 M undefined
2027e27.4 M undefined-66.92 M undefined-29.68 M undefined
2026e30.23 M undefined-58.81 M undefined-49.91 M undefined
2025e35.23 M undefined-23.67 M undefined-28.51 M undefined
2024e475,962.58 undefined-70.82 M undefined-31.51 M undefined
2023391,700 undefined-59.28 M undefined-52.34 M undefined
20221.5 M undefined-55.5 M undefined-54.2 M undefined
2021208.4 M undefined124.2 M undefined119.8 M undefined
202012.6 M undefined-81.4 M undefined-81 M undefined
20190 undefined-61.4 M undefined-60.5 M undefined
20180 undefined-52.9 M undefined-52 M undefined
20170 undefined-65 M undefined-64.8 M undefined
20160 undefined-22.5 M undefined-22.4 M undefined
20150 undefined-13.2 M undefined-13.2 M undefined
20140 undefined-300,000 undefined-300,000 undefined

Ovid Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000001220810035302771121
-------1,633.33-99.52----14.29-10.00162.9670.42
----------------
0000000000000000
0-13-22-64-52-60-81119-54-52-31-28-49-29-29-24
--69.23190.91-18.7515.3835.00-246.91-145.38-3.70-40.38-9.6875.00-40.82--17.24
24.624.624.619.324.639.258.568.170.470.58000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Ovid Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ovid Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
4.869.951.987.141.576.772187.8129105.83
000001.10.1000
0000000000
0000000000
00.30.41.52.81.92.72.72.43.76
4.870.252.388.644.379.774.8190.5131.4109.6
0000.10.10.10.10.216.114.66
00000001.65.617.63
0000000000
000000300200200182.97
0000000000
00.10.60.83.310.6221.96
00.10.60.93.41.11423.934.43
4.870.352.989.547.780.875.8194.5155.3144.03
                   
0000010010010010070.69
581.585.2184.1191.5283.1337.8351357.8365.59
-0.3-13.5-35.9-100.7-152.7-213.2-294.2-171.4-225.5-277.87
0000000000
0000000000
4.76849.383.438.87043.7179.7132.487.8
0.10.70.923.83.35.47.123.7
01.62.945.17.3127.757.77
0000004.6000
0000000000
0000000000
0.12.33.868.910.62214.8711.47
0000000000
0000000000
000000.310.201644.76
000000.310.201644.76
0.12.33.868.910.932.214.82356.23
4.870.353.189.447.780.975.9194.5155.4144.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ovid Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ovid Therapeutics's financial health and stability.

Assets

Ovid Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ovid Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ovid Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ovid Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
0-13-22-64-52-60-81122-54-52
0000000000
0000000000
01010321-16-82
07738141015171310
0000000000
0000000000
0-5-17-31-45-51-51118-55-45
00000000-10
0000-5-3034-1-87-2
0000-5-2935-1-86-2
0000000000
0000000000
57006908647000
570066086470030
000-30000030
0000000000
465-1835-50530117-142-17
-0.2-5.6-18-31.5-46-51.3-52118.4-56.6-45.92
0000000000

Ovid Therapeutics stock margins

The Ovid Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ovid Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ovid Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ovid Therapeutics's sales revenue. A higher gross margin percentage indicates that the Ovid Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ovid Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ovid Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ovid Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ovid Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ovid Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ovid Therapeutics Margin History

Ovid Therapeutics Gross marginOvid Therapeutics Profit marginOvid Therapeutics EBIT marginOvid Therapeutics Profit margin
2029e0 %0 %-20.23 %
2028e0 %-61.22 %-41.25 %
2027e0 %-244.2 %-108.3 %
2026e0 %-194.58 %-165.11 %
2025e0 %-67.18 %-80.94 %
2024e0 %-14,878.29 %-6,620.35 %
20230 %-15,134.4 %-13,362 %
20220 %-3,700 %-3,613.33 %
20210 %59.6 %57.49 %
20200 %-646.03 %-642.86 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Ovid Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Ovid Therapeutics earnings per share therefore indicates how much revenue Ovid Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ovid Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ovid Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ovid Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ovid Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ovid Therapeutics Revenue, EBIT and net profit per share

DateOvid Therapeutics Sales per ShareOvid Therapeutics EBIT per shareOvid Therapeutics Earnings per Share
2029e1.71 undefined0 undefined-0.35 undefined
2028e1.01 undefined0 undefined-0.42 undefined
2027e0.39 undefined0 undefined-0.42 undefined
2026e0.43 undefined0 undefined-0.7 undefined
2025e0.5 undefined0 undefined-0.4 undefined
2024e0.01 undefined0 undefined-0.44 undefined
20230.01 undefined-0.84 undefined-0.74 undefined
20220.02 undefined-0.79 undefined-0.77 undefined
20213.06 undefined1.82 undefined1.76 undefined
20200.22 undefined-1.39 undefined-1.38 undefined
20190 undefined-1.57 undefined-1.54 undefined
20180 undefined-2.15 undefined-2.11 undefined
20170 undefined-3.37 undefined-3.36 undefined
20160 undefined-0.91 undefined-0.91 undefined
20150 undefined-0.54 undefined-0.54 undefined
20140 undefined-0.01 undefined-0.01 undefined

Ovid Therapeutics business model

Ovid Therapeutics Inc. is a US biopharmaceutical company focused on developing targeted therapies for rare neurological disorders. The company was founded in 2014 and is based in New York. Ovid Therapeutics aims to develop a new class of therapeutics based on regulating the GABA receptor in the brain. GABA is a neurotransmitter responsible for inhibiting neuronal activity in the brain. By modulating the GABA receptor through pharmacological interventions, Ovid Therapeutics hopes to achieve a neuroprotective effect and treat a variety of rare neurological disorders. The company's therapies aim to alleviate symptoms of these diseases and improve brain function by targeting the behavior of GABA receptors. Ovid Therapeutics specializes in researching and developing drugs for three specific conditions: Angelman syndrome, Fragile X syndrome, and tuberous sclerosis complex. Ovid Therapeutics' business model is based on a combination of innovative sciences developed in the start-up model and a focus on strategic partnerships and collaborations with other pharmaceutical and biotech companies. The company's core business involves the clinical development of therapeutic options. Ovid Therapeutics follows a dual-track strategy, developing its own pipeline while also pursuing partnerships with other pharmaceutical companies to secure additional funding and research capabilities. Ovid Therapeutics has an extensive portfolio of preclinical and clinical drugs targeting rare neurological disorders with different drug classes and mechanisms of action. In recent years, Ovid Therapeutics has gained an excellent reputation in the scientific community and won numerous awards. Recently, the company was also recognized as "One to Watch" at the second annual BioCentury's "Beyond Borders." Gaboxadol is the first drug brought to market by Ovid Therapeutics. Gaboxadol is a modulator of the GABAb receptor that has shown excellent results in studies for treating Angelman syndrome. Based on such results, the company is now focused on further developing therapeutic options and conducting more research in the field of rare neurological disorders. Ovid Therapeutics has directed its efforts towards addressing the needs of a patient population that has limited treatment options due to rare neurological disorders. Based on the extensive research results the company has already achieved, its goal is to lay the groundwork for developing novel therapeutics and significantly improving the quality of life for affected patients. Ovid Therapeutics is one of the most popular companies on Eulerpool.com.

Ovid Therapeutics SWOT Analysis

Strengths

Ovid Therapeutics Inc has a strong portfolio of innovative therapeutics aimed at addressing unmet medical needs.

The company has a highly skilled and experienced management team, well-versed in drug development and commercialization.

Ovid Therapeutics Inc has established strategic partnerships with leading pharmaceutical companies, providing access to additional resources and expertise.

Weaknesses

Ovid Therapeutics Inc has a relatively small-scale operation compared to some of its competitors, which may limit its ability to rapidly expand and penetrate the market.

The company heavily relies on external funding sources to support its research and development activities, making it vulnerable to changes in the investment landscape.

Ovid Therapeutics Inc faces significant competition from well-established pharmaceutical companies with greater financial and marketing resources.

Opportunities

The increasing prevalence of certain neurological disorders presents a significant market opportunity for Ovid Therapeutics Inc to target with its therapeutic solutions.

Ovid Therapeutics Inc can explore potential collaborations with academic institutions and research organizations to enhance its pipeline and expand into new therapeutic areas.

The company can leverage advancements in technology and data analytics to optimize its drug development processes and improve patient outcomes.

Threats

Regulatory uncertainties and evolving legal frameworks pose a potential threat to Ovid Therapeutics Inc's ability to successfully obtain necessary approvals for its products.

Intense competition within the pharmaceutical industry, along with the presence of generic drug manufacturers, may impact pricing and market share for Ovid Therapeutics Inc.

Adverse events during clinical trials or post-market may lead to setbacks in product development and damage the company's reputation.

Ovid Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Ovid Therapeutics Revenue by Segment

Segmente20222021
Related Party-196 M USD
License-12.38 M USD
License and other revenue1.5 M USD-
License revenue - related party--
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ovid Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ovid Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ovid Therapeutics shares outstanding

The number of shares was Ovid Therapeutics in 2023 — This indicates how many shares 70.581 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ovid Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ovid Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ovid Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ovid Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Ovid Therapeutics.

Ovid Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.23 0.12  (153 %)2024 Q2
3/31/2024-0.22 -0.17  (23.49 %)2024 Q1
12/31/2023-0.05 -0.22  (-333.93 %)2023 Q4
9/30/2023-0.19 -0.16  (16.84 %)2023 Q3
6/30/2023-0.21 -0.18  (13.75 %)2023 Q2
3/31/2023-0.17 -0.19  (-8.76 %)2023 Q1
12/31/2022-0.19 -0.16  (13.93 %)2022 Q4
9/30/2022-0.22 -0.17  (22.2 %)2022 Q3
6/30/2022-0.25 -0.21  (17.23 %)2022 Q2
3/31/2022-0.21 -0.23  (-8.8 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Ovid Therapeutics stock

Eulerpool World ESG Rating (EESG©)

57/ 100

🌱 Environment

56

👫 Social

93

🏛️ Governance

21

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees50
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ovid Therapeutics shareholders

%
Name
Stocks
Change
Date
10.61293 % Takeda Pharmaceutical Co Ltd7,531,99604/9/2024
7.49045 % Rubric Capital Management LP5,315,96906/30/2024
5.75187 % Madison Avenue Partners LP4,082,100433,5916/30/2024
5.43021 % BVF Partners L.P.3,853,81806/30/2024
5.17311 % BlackRock Institutional Trust Company, N.A.3,671,358-142,1396/30/2024
5.14611 % Levin (Jeremy M)3,652,196204/9/2024
4.35310 % The Vanguard Group, Inc.3,089,393113,0856/30/2024
3.52262 % Invus Public Equities Advisors, LLC2,500,00006/30/2024
2.34543 % Acadian Asset Management LLC1,664,5528,6816/30/2024
2.09747 % Kennedy Capital Management LLC1,488,5711,451,1896/30/2024
1
2
3
4
5
...
10

Ovid Therapeutics Executives and Management Board

Dr. Jeremy Levin(69)
Ovid Therapeutics Chairman of the Board, Chief Executive Officer (since 2014)
Compensation 3.13 M
Mr. Jeffrey Rona(54)
Ovid Therapeutics Chief Business and Financial Officer
Compensation 1.61 M
Mr. Jason Tardio(46)
Ovid Therapeutics Chief Operating Officer
Compensation 1.23 M
Mr. Thomas Perone(58)
Ovid Therapeutics Chief Compliance Officer, General Counsel, Corporate Secretary
Compensation 632,106
Mr. Bart Friedman(78)
Ovid Therapeutics Lead Independent Director
Compensation 277,347
1
2
3

Ovid Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Marinus Pharmaceuticals Stock
Marinus Pharmaceuticals
SupplierCustomer0,140,560,730,580,83-0,07
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,750,16-0,47-0,42-0,54-0,08
H Lundbeck Stock
H Lundbeck
SupplierCustomer-0,77-0,36-0,30-0,230,690,52
Takeda Pharmaceutical Stock
Takeda Pharmaceutical
SupplierCustomer-0,930,29-0,53-0,450,130,37
1

Most common questions regarding Ovid Therapeutics

What values and corporate philosophy does Ovid Therapeutics represent?

Ovid Therapeutics Inc represents strong values and a focused corporate philosophy in the field of biopharmaceuticals. The company is dedicated to enhancing the lives of patients and their families by developing innovative therapies for rare neurological disorders. With a commitment to scientific excellence, Ovid Therapeutics is driven by a patient-centric approach, prioritizing their needs and providing potential life-changing solutions. Through strategic partnerships, cutting-edge research, and a deep understanding of the neurological space, Ovid Therapeutics aims to revolutionize the way rare diseases are treated. Their unwavering dedication to making a positive impact makes Ovid Therapeutics Inc a leading force in the biopharmaceutical industry.

In which countries and regions is Ovid Therapeutics primarily present?

Ovid Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Ovid Therapeutics achieved?

Ovid Therapeutics Inc has achieved several significant milestones in its growth and development. The company has successfully initiated Phase 2 clinical trials for its lead product candidate OV101, designed for the treatment of Angelman syndrome and Fragile X syndrome. Ovid Therapeutics Inc has also collaborated with global pharmaceutical companies to advance its research and development efforts. In addition, the company has expanded its pipeline by initiating clinical trials for additional indications. Furthermore, Ovid Therapeutics Inc has successfully raised funding through various financing activities to support its research and development activities. These achievements signify the company's dedication to advancing therapeutic options for patients in need.

What is the history and background of the company Ovid Therapeutics?

Ovid Therapeutics Inc is a biopharmaceutical company specializing in the development of therapies for rare neurological disorders. Founded in 2014, Ovid Therapeutics is focused on delivering innovative treatments for patients with conditions such as Angelman syndrome and Fragile X syndrome. The company's research is centered on understanding the underlying causes of these disorders and developing targeted therapies to address them. Ovid Therapeutics is committed to making significant advancements in the field of neurology and improving the lives of patients with rare neurological conditions through its dedication to scientific excellence and collaboration with healthcare professionals.

Who are the main competitors of Ovid Therapeutics in the market?

The main competitors of Ovid Therapeutics Inc in the market include Sage Therapeutics, Zogenix Inc, and GW Pharmaceuticals.

In which industries is Ovid Therapeutics primarily active?

Ovid Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Ovid Therapeutics?

The business model of Ovid Therapeutics Inc. is focused on developing and commercializing novel therapeutics for patients with rare neurological disorders. They aim to identify and develop potential treatments that address the underlying disease biology and provide meaningful clinical benefits. Ovid Therapeutics Inc. strives to leverage scientific and clinical expertise to advance their pipeline of investigational therapies, collaborating with key partners to drive innovation in the field of rare diseases. Their commitment to patients and their families drives their efforts to bring forth innovative solutions and improve the lives of those affected by rare neurological disorders.

What is the P/E ratio of Ovid Therapeutics 2024?

The Ovid Therapeutics P/E ratio is -2.36.

What is the P/S ratio of Ovid Therapeutics 2024?

The Ovid Therapeutics P/S ratio is 155.97.

What is the Quality Investing of Ovid Therapeutics?

The Quality Investing for Ovid Therapeutics is 2/10.

What is the revenue of Ovid Therapeutics 2024?

The expected Ovid Therapeutics revenue is 475,962.58 USD.

How high is the profit of Ovid Therapeutics 2024?

The expected Ovid Therapeutics profit is -31.51 M USD.

What is the business model of Ovid Therapeutics

Ovid Therapeutics Inc is a biotechnology company focused on developing medications for rare neurological disorders. The company works closely with leading research institutions and pharmaceutical partners to develop a wide range of therapeutics tailored to the individual needs of patients. Ovid Therapeutics' business activities center around three pillars: research and development, partnerships, and commercial activities. The company takes an innovative approach in the field of neuroscience, working on the discovery and development of medications for rare neurological disorders using specialized molecular technologies and knowledge of disease pathophysiology. The main product of Ovid Therapeutics is the investigational drug OV101. This medication is being developed for the treatment of Angelman syndrome (AS) and is currently in Phase 3 of clinical development. OV101 is a highly selective inhibitor of the enzyme GABA-transaminase and aims to maintain GABA signaling, which is crucial for maintaining normal brain function. In addition to OV101, Ovid Therapeutics also has other medications in development, such as the investigational drug OV935 for rare forms of epilepsy and for Angelman syndrome patients with sleep disorders. OV935 is a selective inhibitor of the enzymes TDO and IDO and aims to inhibit the formation of kynurenine signaling, which is responsible for neurological disorders. To further advance these innovative therapeutic approaches in clinical trials, Ovid Therapeutics has formed partnerships with leading research institutions such as Columbia University and the University of Oxford. Additionally, the company collaborates with other biotechnology and pharmaceutical companies to support the research and development of its medications. To promote the introduction and commercialization of its medications, Ovid Therapeutics also has a commercial division. In this department, the company develops marketing strategies and distribution models to successfully position its products in the market. Overall, Ovid Therapeutics focuses on the discovery, development, and commercialization of groundbreaking therapeutics for rare neurological disorders. The close collaboration with leading research institutions and pharmaceutical partners has allowed the company to develop innovative medications aimed at meeting the individual needs of patients. With its various divisions and innovative approach, Ovid Therapeutics has become a pioneering company in the field of neuroscience.

What is the Ovid Therapeutics dividend?

Ovid Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Ovid Therapeutics pay dividends?

The dividend cannot currently be calculated for Ovid Therapeutics or the company does not pay out a dividend.

What is the Ovid Therapeutics ISIN?

The ISIN of Ovid Therapeutics is US6904691010.

What is the Ovid Therapeutics WKN?

The WKN of Ovid Therapeutics is A2DQ8S.

What is the Ovid Therapeutics ticker?

The ticker of Ovid Therapeutics is OVID.

How much dividend does Ovid Therapeutics pay?

Over the past 12 months, Ovid Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ovid Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Ovid Therapeutics?

The current dividend yield of Ovid Therapeutics is .

When does Ovid Therapeutics pay dividends?

Ovid Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ovid Therapeutics?

Ovid Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ovid Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ovid Therapeutics located?

Ovid Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ovid Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ovid Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Ovid Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Ovid Therapeutics in the year 2023?

In the year 2023, Ovid Therapeutics distributed 0 USD as dividends.

In which currency does Ovid Therapeutics pay out the dividend?

The dividends of Ovid Therapeutics are distributed in USD.

All fundamentals about Ovid Therapeutics

Our stock analysis for Ovid Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ovid Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.